{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:46:29Z","timestamp":1791254789625,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T00:00:00Z","timestamp":1752364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40120-025-00784-0","type":"journal-article","created":{"date-parts":[[2025,7,13]],"date-time":"2025-07-13T04:27:57Z","timestamp":1752380877000},"page":"1975-1992","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Five-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03650114","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-4001","authenticated-orcid":false,"given":"Stephen L.","family":"Hauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"de S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Giacomini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibyl","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alit","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Jehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseanne","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibolya","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,13]]},"reference":[{"key":"784_CR1","unstructured":"Kesimpta Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf. Accessed December 12, 2024."},{"key":"784_CR2","unstructured":"Kesimpta. Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125326s070lbl.pdf. Accessed December 12, 2024."},{"key":"784_CR3","unstructured":"Novartis Kesimpta\u00ae six-year efficacy data show substantial benefits in recently diagnosed treatment-na\u00efve people with relapsing multiple sclerosis. https:\/\/www.novartis.com\/us-en\/news\/media-releases\/novartis-kesimpta-six-year-efficacy-data-show-substantial-benefits-recently-diagnosed-treatment-naive-people-relapsing-multiple-sclerosis. Accessed December 12, 2024."},{"key":"784_CR4","unstructured":"Novartis. Data on file. Kesimpta PSUR. Sep 2024."},{"key":"784_CR5","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40120-023-00518-0","volume":"12","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Kappos L, Bar-Or A, et al. The development of ofatumumab, a fully human anti-CD20 monoclonal antibody for practical use in relapsing multiple sclerosis treatment. Neurol Ther. 2023;12:1491\u2013515. https:\/\/doi.org\/10.1007\/s40120-023-00518-0.","journal-title":"Neurol Ther"},{"key":"784_CR6","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. B-cell depletion and efficacy outcomes with ofatumumab: subgroup analysis from the pooled phase 3 ASCLEPIOS I and II trials. Poster presented at: 72nd American Academy of Neurology Annual meeting; ePoster P7-9-013."},{"key":"784_CR7","doi-asserted-by":"publisher","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","volume":"90","author":"A Bar-Or","year":"2018","unstructured":"Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90:e1805\u201314. https:\/\/doi.org\/10.1212\/WNL.0000000000005516.","journal-title":"Neurology"},{"key":"784_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M, Thompson A, Hartung HP, et al. Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol. 2024;271:105\u201315. https:\/\/doi.org\/10.1007\/s00415-023-11969-8.","journal-title":"J Neurol"},{"key":"784_CR9","doi-asserted-by":"publisher","first-page":"175628642110195","DOI":"10.1177\/17562864211019574","volume":"14","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano P, Lucisano G, Caputo F, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:17562864211019574. https:\/\/doi.org\/10.1177\/17562864211019574.","journal-title":"Ther Adv Neurol Disord"},{"key":"784_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"key":"784_CR11","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1177\/13524585221078825","volume":"28","author":"J Gartner","year":"2022","unstructured":"Gartner J, Hauser SL, Bar-Or A, et al. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: results from ASCLEPIOS I and II. Mult Scler. 2022;28:1562\u201375. https:\/\/doi.org\/10.1177\/13524585221078825.","journal-title":"Mult Scler"},{"key":"784_CR12","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/13524585231195346","volume":"29","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Zielman R, Das Gupta A, et al. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension. Mult Scler. 2023;29:1452\u201364. https:\/\/doi.org\/10.1177\/13524585231195346.","journal-title":"Mult Scler"},{"key":"784_CR13","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/13524585211044479","volume":"28","author":"A Bar-Or","year":"2022","unstructured":"Bar-Or A, Wiendl H, Montalban X, et al. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022;28:910\u201324. https:\/\/doi.org\/10.1177\/13524585211044479.","journal-title":"Mult Scler"},{"key":"784_CR14","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1177\/13524585211055934","volume":"28","author":"JI Kira","year":"2022","unstructured":"Kira JI, Nakahara J, Sazonov DV, et al. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: phase 2 APOLITOS study. Mult Scler. 2022;28:1229\u201338. https:\/\/doi.org\/10.1177\/13524585211055934.","journal-title":"Mult Scler"},{"key":"784_CR15","unstructured":"ClinicalTrials.gov. NCT03650114. Long-term safety, tolerability and effectiveness study of ofatumumab in patients with relapsing MS (ALITHIOS). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03650114. Accessed May 7, 2025."},{"key":"784_CR16","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/13524585221079731","volume":"28","author":"SL Hauser","year":"2022","unstructured":"Hauser SL, Cross AH, Winthrop K, et al. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Mult Scler. 2022;28:1576\u201390. https:\/\/doi.org\/10.1177\/13524585221079731.","journal-title":"Mult Scler"},{"key":"784_CR17","first-page":"45","volume":"47","author":"International Conference on Harmonisation","year":"2001","unstructured":"International Conference on Harmonisation. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med. 2001;47:45\u201350.","journal-title":"J Postgrad Med"},{"key":"784_CR18","unstructured":"World Medical Association. WMA Declaration of Helsinki: ethical principles for medical research involving human subjects. 2006 https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 7 Mar 2025."},{"key":"784_CR19","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Published November 27, 2017. Accessed December 12, 2024."},{"key":"784_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(20)30067-3.","journal-title":"Lancet Neurol"},{"key":"784_CR21","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1212\/WNL.0000000000207664","volume":"101","author":"A Cobo-Calvo","year":"2023","unstructured":"Cobo-Calvo A, Tur C, Otero-Romero S, et al. Association of very early treatment initiation with the risk of long-term disability in patients with a first demyelinating event. Neurology. 2023;101:e1280\u201392. https:\/\/doi.org\/10.1212\/WNL.0000000000207664.","journal-title":"Neurology"},{"key":"784_CR22","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, Haring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145:3147\u201361. https:\/\/doi.org\/10.1093\/brain\/awac016.","journal-title":"Brain"},{"key":"784_CR23","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Hollenbach JA, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85:653\u201366. https:\/\/doi.org\/10.1002\/ana.25463.","journal-title":"Ann Neurol"},{"key":"784_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537.","journal-title":"JAMA Neurol"},{"key":"784_CR25","doi-asserted-by":"publisher","first-page":"205521732311547","DOI":"10.1177\/20552173231154712","volume":"9","author":"R Alonso","year":"2023","unstructured":"Alonso R, Casas M, Lazaro L, et al. Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies. Mult Scler J Exp Transl Clin. 2023;9:20552173231154710. https:\/\/doi.org\/10.1177\/20552173231154712.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"784_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","volume":"79","author":"A Cagol","year":"2022","unstructured":"Cagol A, Schaedelin S, Barakovic M, et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol. 2022;79:682\u201392. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1025.","journal-title":"JAMA Neurol"},{"key":"784_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jnnp-2014-309903","volume":"87","author":"N De Stefano","year":"2016","unstructured":"De Stefano N, Stromillo ML, Giorgio A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:93\u20139. https:\/\/doi.org\/10.1136\/jnnp-2014-309903. (Epub 2015 Apr 22 PMID: 25904813).","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"784_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/1352458517742739","volume":"25","author":"T Uher","year":"2019","unstructured":"Uher T, Vaneckova M, Krasensky J, et al. Pathological cut-offs of global and regional brain volume loss in multiple sclerosis. Mult Scler. 2019;25:541\u201353. https:\/\/doi.org\/10.1177\/1352458517742739.","journal-title":"Mult Scler"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00784-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:22:38Z","timestamp":1758367358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,13]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00784-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,13]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stephen L. Hauser currently serves on the scientific advisory boards of Accure, Alector, and Annexon. He has previously consulted for BD, Moderna, NGM Bio, and Pheno Therapeutics and served on the Board of Directors of Neurona. Dr. Hauser also has received travel reimbursement and writing support from F. Hoffmann-La Roche and Novartis AG for anti-CD20 therapy\u2013related meetings and presentations. Grants: NIH\/NINDS (R35NS111644), NMSS (SI-2001-35701), and Valhalla Foundation. Jeffrey A. Cohen received personal compensation for consulting for Astoria, Bristol-Myers Squibb, Convelo, and Viatris, as well as chairing a DSMB for Celltrion. J\u00e9r\u00f4me de Seze received personal compensation from Alexion, Biogen, F. Hoffmann-La Roche Ltd, Sanofi, LFB, Merck, Novartis, Horizon-Amgen, Argenx, and UCB. Sven G. Meuth has received honoraria for consulting from Alexion, Almirall, Amicus Therapeutics Germany, Bayer Healthcare, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. He received a research grant from German Ministry for Education and Research (BMBF), Bundesinstitut f\u00fcr Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kr\u00f6ner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Centre for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva. Paul S. Giacomini has received honoraria for consulting, speaking, and advisory board participation from Actelion, Alexion, Biogen Idec, Bristol Myers Squibb-Celgene, EMD Serono, Genzyme-Sanofi, Innodem Neurosciences, Novartis, Pendopharm, Roche, and Teva Neuroscience. Jin Nakahara received speaker honoraria from AbbVie, Alexion, Astellas, Biogen, Chugai, CSL-Behring, Daiichi-Sankyo, Eisai, Fujimoto Pharma, JB, Mitsubishi-Tanabe, Novartis, Otsuka, Sanofi, Sumitomo Dainippon, and Takeda. He is acting as a paid consultant for Alexion, Biogen, Chugai, Mitsubishi-Tanabe, and Novartis. His research is supported by AbbVie, Biogen, B\u00f6ehringer-Ingelheim, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, JB, Keio University, Kyowa-Kirin, Mitsubishi-Tanabe, MEXT, MHLW, MSD, Otsuka, Pfizer, Shionogi, Sumitomo Dainippon, Takeda, and Tsumura. Celia Oreja-Guevara has received fees for lectures and consultations from Biogen Idec, Celgene, Sanofi-Genzyme, Novartis, BMS, Jannsen, Roche, Merck, and Teva. Derrick Robertson has received fees for consulting, contract research, and speaker bureau from Biogen, Celgene, EMD Serono, Genentech, Sanofi Genzyme, Janssen, and TG therapeutics; consulting and speaker bureau from Bristol Myers Squibb, Horizon, and Alexion; consulting and contract research from Novartis; consulting from Greenwich Biosciences; and contract research from GW Pharmaceuticals, PCORI, Atara Biotherapeutics, and CorEvitas. Sibyl Wray received fees for consulting and advisory boards for Biogen, Celgene, and EMO Serano; speaker bureaus from Biogen, Celgene, EMO Serano, Genentech-Roche, and Sanofi-Genzyme; and research support from Biogen, Celgene, EMO Serono, Genentech-Roche, Novartis, Receptos, Sanofi-Genzyme, and TG Therapeutics. Heinz Wiendl declares that he has acted as a member of the Scientific Advisory Boards of Alexion, Argenx, Biocryst, Bristol Myers Squibb, Cellerys, Galapagos, Janssen, Merck, Novartis, Sandoz-Hexal, and Uniqure. He also declares that he has received speaker honoraria and travel support from Alexion, Biogen, Bristol Myers Squibb, EPG Health, Genzyme, Merck, Neurodiem, Novartis, Ology, Roche, Teva, and WebMD Global and acts as a paid consultant for AbbVie, Actelion, Argenx, Biogen, Bristol Myers Squibb, and EMD Serono. He is acting as a paid consultant for Actelion, Argenx, BD, Bristol Myers Squibb, Dianthus, EMD Serono, EPG Health, Fondazione Cariplo, Gossamer Bio, Idorsia, Immunic, Immunovant, Inmune Bio, Syneos Health, Janssen, LTS, Merck, NexGen, Novartis, Roche, Samsung, Sangamo, Sanofi, Swiss Multiple Sclerosis Society, Toleranzia, UCB, Viatris, VirBio, and Worldwide Clinical Trials. His research is funded by Alexion, Amicus Therapeutics, Argenx, Biogen, CSL Behring, F. Hoffmann-La Roche, Genzyme, Merck, Novartis, Roche, and UCB. Ludwig Kappos\u2019 institution (University Hospital Basel) has received the following exclusively for research support: Steering committee, advisory board and\/or consultancy fees from Biogen, EMD Serono Research and Development, Genentech, Janssen, Novartis, Clene Nanomedicine Inc., Bayer, Bristol Myers Squibb, Celltrion Inc., Eli Lilly (Suisse) SA, Galapagos NV, Kiniksa Pharmaceuticals, Merck Healthcare AG, Minoryx and Santhera, Neurostatus UHB AG, Roche, Sanofi, Santhera Pharmaceuticals, Shionogi BV, Wellmera AG, and Zai Lab; speaker fees from Bristol Myers Squibb, Janssen, Novartis, Roche, and Sanofi; grants from the European Union, Innosuisse, Merck Healthcare AG, Novartis, and Roche; and testimony. Alit Bhatt, Xixi Hu, Jing Xi, Rebecca Piccolo, Valentine Jehl, Roseanne Sullivan, and Ibolya Boer are employees of Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These clinical studies were designed and implemented, executed, and reported in accordance with the International Conference on Harmonisation Tripartite guidelines for Good Clinical Practice [\n                      \n                      ] with applicable local regulations (including European Directive 2001\/20\/EC, US CFR 21), and with the ethical principles laid down in the Declaration of Helsinki [\n                      \n                      ]. The protocol was approved by an institutional review board or ethics committee at each trial site. All the patients or their legal representatives provided written informed consent before commencing trial-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}